42 completed. 42 Phase 2, 12 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 42 | Completed 42 |
| Phase 1 | 12 | Completed 12 |
| Phase 3 | 3 | Completed 3 |
Follow Neoplasms, Multiple Primary: new trials by email Literature Review of Neoplasms, Multiple Primary trials Research Report on Neoplasms, Multiple Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy LP352, bexicaserin - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 2 | Completed | Longboard Pharmaceuticals | 41 | 2022-11-08 | 2025-12-03 |
| Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 1 / Phase 2 | Completed | Longboard Pharmaceuticals | 52 | 2022-03-03 | 2024-11-08 |
| Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC Basimglurant with crossover to Placebo, Placebo with crossover to Basimglurant - Tuberous Sclerosis Complex | Phase 2 | Completed | Noema Pharma AG | 61 | 2022-03-03 | 2025-06-04 |
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients Alpelisib, Metformin, Fulvestrant - Breast Cancer | Phase 2 | Completed | MedSIR | 69 | 2020-10-23 | 2025-07-29 |
| Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants TAVT-18 (sirolimus) - Tuberous Sclerosis Complex, Epilepsy | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 5 | 2020-09-08 | 2024-05-16 |
| Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) Ganaxolone - Tuberous Sclerosis | Phase 2 | Completed | Marinus Pharmaceuticals | 23 | 2020-04-08 | 2023-04-04 |
| Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women Blueberry Powder, Placebo Powder - Hypertension, Aging | Phase 1 / Phase 2 | Completed | Colorado State University | 60 | 2020-01-01 | 2026-10-30 |
| Sirolimus for Cowden Syndrome With Colon Polyposis Sirolimus - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | Phase 2 | Completed | Ohio State University | 5 | 2019-09-16 | 2025-06-10 |
| Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex rapamycin, placebo - Facial Angiofibroma, Tuberous Sclerosis | Phase 2 / Phase 3 | Completed | Dermatology Specialties Limited Partnership | 107 | 2019-07-28 | 2023-09-08 |
| Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception Nestorone + Testosterone Combination Gel - Healthy, Men | Phase 2 | Completed | Premier Research | 420 | 2018-10-25 | 2025-02-18 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies TAK-935, Placebo - Epilepsy, Dravet Syndrome | Phase 2 | Completed | Takeda | 141 | 2018-08-08 | 2026-09-14 |
| Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men Dimethandrolone-Undecanoate, Levonorgestrel 0.03 MG, Placebo oral capsule - Healthy, Men | Phase 2 | Completed | Premier Research | 92 | 2018-04-16 | 2025-10-30 |
| RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome RAD001, Placebo - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 46 | 2017-06-12 | 2025-02-17 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
| Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex Early Vigabatrin, Delayed Vigabatrin (Placebo) - Tuberous Sclerosis Complex | Phase 2 | Completed | Martina Bebin | 84 | 2016-12-01 | 2024-08-19 |
| Effect of PROGRESSive Training and Teststerone in Older Frail Men testosterone, Progressive muscle training - Muscle Weakness | Phase 2 / Phase 3 | Completed | University Hospital, Gentofte, Copenhagen | 192 | 2016-11-01 | 2024-05-29 |
| Everolimus for Cancer With TSC1 or TSC2 Mutation Everolimus - TSC1, TSC2 | Phase 2 | Completed | Dana-Farber Cancer Institute | 30 | 2014-09-01 | 2020-09-16 |
| Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept - Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2014-06-18 | 2020-03-23 |
| Safety of Simvastatin in LAM and TSC Simvastatin, Sirolimus Oral Product, Everolimus Oral Product - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 10 | 2014-03-01 | 2020-08-25 |
| Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT - Prostate Cancer | Phase 2 | Completed | Medical College of Wisconsin | 48 | 2014-03-01 | 2023-09-22 |
Showing 20 of 42. Sign in to see all of them.
Tuberous Sclerosis (20) · Multiple Endocrine Neoplasia Type 1 (13) · Epilepsy (7) · Hamartoma Syndrome, Multiple (4) · Hereditary Sensory and Autonomic Neuropathies (4) · Autistic Disorder (3) · Breast Neoplasms (3) · CDKL5 deficiency disorder (3) · Carcinoma, Medullary (3) · Epilepsies, Myoclonic (3) · Lennox Gastaut Syndrome (3) · Lymphangioleiomyomatosis (3) · Multiple Endocrine Neoplasia (3) · Multiple Endocrine Neoplasia Type 2a (3) · Seizures (3)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (42) · Genetic Diseases, Inborn (42) · Neoplastic Syndromes, Hereditary (42) · Neoplasms (40) · Hamartoma (24) · Nervous System Diseases (23) · Congenital Abnormalities (21) · Heredodegenerative Disorders, Nervous System (21) · Nervous System Malformations (21) · Neurodegenerative Diseases (21) · Malformations of Cortical Development, Group I (20) · Neurocutaneous Syndromes (20) · Malformations of Cortical Development (19) · Neoplasms by Site (18)
Everolimus (10) · Sirolimus (9) · 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine (1) · 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethylphenyl)-1,3-dihydroimidazo(4,5-c)quinolin-2-one (1) · Alpelisib (1) · Anastrozole (1) · Arginine (1) · Autogenic Training (1) · Cytidine Triphosphate (1) · Erythromycin (1) · Ethanol (1) · Fluorodeoxyglucose F18 (1) · Fulvestrant (1) · Glutamine (1) · Interpersonal Psychotherapy (1)
Children's Hospital Medical Center, Cincinnati (6) · National Cancer Institute (NCI) (5) · Dana-Farber Cancer Institute (2) · Longboard Pharmaceuticals (2) · Premier Research (2) · Astellas Pharma Inc (1) · Beth Israel Deaconess Medical Center (1) · Boston Children's Hospital (1) · Colorado State University (1) · Dermatology Specialties Limited Partnership (1) · Federico II University (1) · Hoffmann-La Roche (1) · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1) · Marinus Pharmaceuticals (1) · Martina Bebin (1)
United States (39) · Spain (6) · Australia (5) · Italy (4) · Canada (3) · United Kingdom (3) · China (2) · Israel (2) · Poland (2) · Taiwan (2) · Belgium (1) · Chile (1) · Czechia (1) · Denmark (1) · France (1)
Dennis J Dlugos, MD (2) · John Bissler, MD (2) · Mustafa Sahin, MD, PhD (2) · Andrew Herzog, M.D., M.Sc. (1) · Annamaria Colao, MD, PhD (1) · Antonio Llombart (1) · Arun Rajan, M.D. (1) · Bhavana Konda (1) · Brigitte C Widemann, M.D. (1) · Christopher Gardner (1) · Daniel Halperin (1) · Darcy Krueger, M.D. Ph.D (1) · Darcy Krueger, MD, PhD (1)
PMID 18184959, PMID 21047224, PMID 21482669, PMID 21915260, PMID 22262746, PMID 23325902, PMID 23344409, PMID 23437092, PMID 23766359, PMID 23798472, PMID 24617713, PMID 25578927, PMID 25956795, PMID 25972901, PMID 26381530, PMID 29023494, PMID 29187393, PMID 29500160, PMID 29800048, PMID 30424962, PMID 31350329, PMID 31912454, PMID 34118197, PMID 34118198, PMID 35587487, PMID 35594551, PMID 35715405, PMID 35841234, PMID 35962206, PMID 36347310, PMID 37282666, PMID 37463422, PMID 37638552, PMID 37916501, PMID 37934000, PMID 38009200, PMID 39289825, PMID 39331837, PMID 40478255, PMID 40639400, PMID 41886723
P30CA016672 (2), 2016 (1), 2018 (1), 2019 (1), N01CM00039 (1), N01CM00070 (1), N01CM62202 (1), N01CM62207 (1), P01DK068055 (1), P30CA006516 (1), P30CA016058 (1), R01CA107164 (1), R21CA103486 (1), U01CA062490 (1), U01NS092595 (1)